SUNDAY, FEBRUARY 6
Arrival and Registration

MONDAY, FEBRUARY 7
Welcome and Keynote Session (Joint)
Robert V. Farese Jr., Harvard School of Public Health, USA
Tobias Walther, Harvard/HHMI, USA
Dissecting Lipid Droplets: From Mechanisms to New Therapies

Adipose Tissue Crosstalk in Metabolic Diseases (Joint)
Camilla Charlotte Schéele, University of Copenhagen, Denmark
Yu-Hua Tseng, Joslin Diabetes Center/Harvard Medical School, USA
Edward T. Chouchani, Dana-Farber Cancer Institute, USA
Succinate Regulation of Metabolism

Short Talk(s) Chosen from Abstracts

Workshop: Industry Clinical Trials in NASH (Q1)
*Saswata Talukdar, Merck, USA
Short Talks Chosen from Abstracts

The Gut-Liver Axis (Q1)
Lotte Bjerre Knudsen, Novo Nordisk A/S, Denmark
GLP 1 Receptor Agonists: Mechanisms Relevant for the Treatment of NASH
Greg Steinberg, McMaster University, Canada
Gut-Endocrine Factors in NASH
Arun J. Sanyal, Virginia Commonwealth University Medical Center, USA
Role of the Gut Microbiome as a Biomarker and Therapeutic Target in NASH

Short Talk(s) Chosen from Abstracts

Factors that Improve Fat Function, but not Mass (Q2)
Ruth J. F. Loos, Mount Sinai School of Medicine, USA
Obesity Uncoupling Obesity from Metabolic Complications
Jacqueline M. Stephens, Louisiana State University, USA
Pathways that Modulate Adipocyte Function and Improve Systemic Metabolic Function
Andrew J. Whittle, Novo Nordisk, USA
Obesity Research

Short Talk(s) Chosen from Abstracts

TUESDAY, FEBRUARY 8
Inflammation, Fibrosis and Metabolism (Q1)
Ido Amit†, Weizmann Institute, Israel
Lipid Associated Macrophages and TREM2
Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA
Hepatic Stellate Cells and Liver Fibrosis
Katrin J. Svensson, Stanford University, USA
Novel Secreted Factors Regulating Metabolism

Nuts and Bolts of Adipocyte Biology (Q2)
Ursula A. White, Pennington Biomedical Research Center, USA
Regulation of Adipocyte Turnover in vivo-Influence of Depot, Race, and Exercise
Kirsty L. Spalding, Karolinska Institute, Sweden
Dynamics of Fat Cell Turnover in Humans
Samuel Virtue, University of Cambridge Metabolic Research Laboratories, UK
Mouse Models with Altered Metabolic Flexibility

Speaker to be Announced
Short Talk(s) Chosen from Abstracts

Emerging Technologies for the Study of Tissue Crosstalk (Q1)
Natalie Krahmer, Helmholtz Zentrum München, Germany
Unbiased Proteomics to Discover Biomarkers and Therapeutic Targets in NASH
Takanori Takebe, Cincinnati Children's Hospital Medical Center, Japan
Modeling Steatohepatitis in Humans with Liver Organoids

Short Talk(s) Chosen from Abstracts

Muscle-Liver Cross-Talk (Q1)
Matthew Watt, University of Melbourne, Australia
Hepatokines Regulating Muscle Metabolism
Bente Klarlund Pedersen, University of Copenhagen, Denmark
Muscle-organ Cross-Talk – Focus on IL-6
Isabelle Leclercq, Université catholique de Louvain, Belgium
Sarcopenic Obesity and NASH

Short Talk(s) Chosen from Abstracts

Influences of Adipose Tissue Immune Cells (Q2)
Myriam Aouadi, Karolinska Institutet, Sweden
Macrophages Influence on Metabolism beyond Inflammation
Vishwa Deep Dixit, Yale University, USA
Aging and Adipose Tissue inflammation

* Session Chair † Invited but not yet accepted  Program current as of May 8, 2021. Meal formats are based on meeting venue. For the most up-to-date details, visit https://www.keystonesymposia.org.
KEYSTONE SYMPOSIA
on Molecular and Cellular Biology

Inter Organ Crosstalk in Non-Alcoholic Steatohepatitis (NASH) (Q1)
Scientific Organizers: Greg Steinberg, Camilla Charlotte Schéele and Saswata Talukdar
Supported by the Directors’ Fund

Adipose Tissue and Metabolic Health (Q2)
Scientific Organizers: Jacqueline M. Stephens and Antonio J. Vidal-Puig
February 6-9, 2022 • Keystone Resort • Keystone, CO, USA
Supported by the Directors’ Fund


THURSDAY, FEBRUARY 10

Departure

Poster Session 2

WEDNESDAY, FEBRUARY 9

NASH Therapeutics (Q1)

Mary E. Rinella, Northwestern University, USA
Recent Advances of Defining Endpoints in NASH
Clinical Trials

Sophie Bozec, Poxel SA, France
PXL770 a Direct AMPK Activator for the Treatment of NASH

Saswata Talukdar, Merck, USA
New Advances in NASH Therapies

Short Talk(s) Chosen from Abstracts

Alternate Models of Disease and Metabolism (Q2)

Speaker to be Announced

Jennifer Watts, Washington State University, USA
Using C. elegans to Study Lipid Synthesis and Function

Fiona Oakley, Newcastle University, UK
Bioreactor Technology for Modeling Fibrosis in Human and Rodent Liver

Marcel den Hoed, Uppsala University, Sweden
Using Zebrafish Larvae to Characterize Candidate Genes for Cardiometabolic Health

Short Talk(s) Chosen from Abstracts

Liver Lipid Metabolism and Signaling Molecules (Q1)

Chen-Yu Zhang, Nanjing University, China
Liver-Islet Communication: Role of miRNAs

Yaron Rotman, NIDDK, National Institutes of Health, USA
Genetic Regulation of Liver Lipid Metabolism

Anna Mae Diehl, Duke University, USA
Novel Liver Derived Cytokines

Short Talk(s) Chosen from Abstracts

Adipose Tissue Microenvironment:
Fibrosis/Extracellular Matrix Remodeling (Q2)

Karine Clément, INSERM / Sorbonne Universite, France
Human Adipose Tissue Fibrosis

Antonio J. Vidal-Puig, University of Cambridge, UK
Uncoupling of Adipose Tissue Fibrosis from Inflammation

Silvia Corvera, University of Massachusetts Medical School, USA
Adipose Tissue Angiogenesis

Short Talk(s) Chosen from Abstracts

* Session Chair † Invited but not yet accepted     Program current as of May 8, 2021. Meal formats are based on meeting venue. For the most up-to-date details, visit https://www.keystonesymposia.org.
KEYSTONE SYMPOSIA
on Molecular and Cellular Biology

Inter Organ Crosstalk in Non-Alcoholic Steatohepatitis (NASH) (Q1)
Scientific Organizers: Greg Steinberg, Camilla Charlotte Schéele and Saswata Talukdar
Supported by the Directors' Fund

Meeting Wrap-Up: Outcomes and Future Directions
(Organizers) (Q1)

Meeting Wrap-Up: Outcomes and Future Directions
(Organizers) (Q2)

Adipose Tissue and Metabolic Health (Q2)
Scientific Organizers: Jacqueline M. Stephens and Antonio J. Vidal-Puig
February 6-9, 2022 • Keystone Resort • Keystone, CO, USA
Supported by the Directors' Fund